Prostacyclin and milrinone by aerosolization improve pulmonary hemodynamics in newborn lambs with experimental pulmonary hypertension

Journal of Applied Physiology

Volumn 109, Issue 3, 2010, Pages 677-684

  Kumar, Vasanth H ^a   Swartz, Daniel D ^a   Rashid, Nasir ^a   Lakshminrusimha, Satyan ^a   Ma, Changxing ^b   Ryan, Rita M ^a   Morin III, Frederick C ^c  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF VERMONT   (United States)

Author keywords

Persistent pulmonary hypertension of the newborn; Pulmonary arterial pressure; Pulmonary blood flow; Pulmonary vascular resistance; Systemic blood pressure

Indexed keywords

ANTIHYPERTENSIVE AGENT; INDOMETACIN; MILRINONE; N(G) NITROARGININE METHYL ESTER; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN; VASODILATOR AGENT;

AEROSOL; ANIMAL; ARTICLE; BLOOD PRESSURE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; HEMODYNAMICS; INHALATIONAL DRUG ADMINISTRATION; LUNG CIRCULATION; NEWBORN; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; SHEEP; VASCULAR RESISTANCE; VASODILATATION;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; ANIMALS, NEWBORN; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EPOPROSTENOL; HEMODYNAMICS; HYPERTENSION, PULMONARY; INDOMETHACIN; MILRINONE; NG-NITROARGININE METHYL ESTER; PHOSPHODIESTERASE INHIBITORS; PULMONARY CIRCULATION; SHEEP; VASCULAR RESISTANCE; VASODILATION; VASODILATOR AGENTS;

EID: 77957167464     PISSN: 87507587     EISSN: 15221601     Source Type: Journal    
DOI: 10.1152/japplphysiol.01082.2009     Document Type: Article

References (37)

1. Bindl L, Fahnenstich H, Peukert U. Aerosolised prostacyclin for pulmonary hypertension in neonates. Arch Dis Child Fetal Neonatal Ed 71: F214-216, 1994.
2. Chang AC, Atz AM, Wernovsky G, Burke RP, Wessel DL. Milrinone: systemic and pulmonary hemodynamic effects in neonates after cardiac surgery. Crit Care Med 23:1907-1914, 1995.
3. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT, Levy PS, Pietra GG, Reid LM, Reeves JT, Rich S, Vreim CE, Williams GW, Wu M. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115:343-349, 1991.
4. De Jaegere AP, van den Anker JN. Endotracheal instillation of prostacyclin in preterm infants with persistent pulmonary hypertension. Eur Respir J 12:932-934, 1998.
5. Dhand R, Tobin MJ. Inhaled bronchodilator therapy in mechanically ventilated patients. Am J Respir Crit Care Med 156:3-10, 1997.
6. Givertz MM, Hare JM, Loh E, Gauthier DF, Colucci WS. Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: a rapid test for reversibility of pulmonary hypertension. J Am Coll Cardiol 28:1775-1780, 1996.
7. Habler O, Kleen M, Zwissler B, Pusch R, Welte M, Vogelmeier C, Kempter B, Krombach F, Messmer K. Inhalation of prostacyclin (PGI2) for 8 hours does not produce signs of acute pulmonary toxicity in healthy lambs. Intensive Care Med 22:426-433, 1996.
8. Hache M, Denault A, Belisle S, Robitaille D, Couture P, Sheridan P, Pellerin M, Babin D, Noel N, Guertin MC, Martineau R, Dupuis J. Inhaled epoprostenol (prostacyclin) and pulmonary hypertension before cardiac surgery. J Thorac Cardiovasc Surg 125:642-649, 2003.
9. Haraldsson A, Kieler-Jensen N, Nathorst-Westfelt U, Bergh CH, Ricksten SE. Comparison of inhaled nitric oxide and inhaled aerosolized prostacyclin in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. Chest 114:780-786, 1998.
10. Haraldsson A, Kieler-Jensen N, Ricksten SE. Inhaled prostacyclin for treatment of pulmonary hypertension after cardiac surgery or heart transplantation: a pharmacodynamic study. J Cardiothorac Vasc Anesth 10:864-868, 1996.
11. Haraldsson A, Kieler-Jensen N, Ricksten SE. The additive pulmonary vasodilatory effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension. Anesthes Analges 93:1439-1445, 2001.
12. Hentschel T, Yin N, Riad A, Habbazettl H, Weimann J, Koster A, Tschope C, Kuppe H, Kuebler WM. Inhalation of the phosphodiesterase-3 inhibitor milrinone attenuates pulmonary hypertension in a rat model of congestive heart failure. Anesthesiology 106:124-131, 2007.
13. Kelly LK, Porta NF, Goodman DM, Carroll CL, Steinhorn RH. Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide. J Pediatr 141:830-832, 2002.
14. Lakshminrusimha SP, Porta NF, Farrow KN, Chen B, Gugino S, Kumar VH, Russel JA, Steinhorn RH. Milrinone enhances relaxation to prostacyclin and iloprost in pulmonary arteries isolated from lambs with persistent pulmonary hypertension of the newborn. Pediatr Crit Care Med 10:2009.
15. Lindsay CA, Barton P, Lawless S, Kitchen L, Zorka A, Garcia J, Kouatli A, Giroir B. Pharmacokinetics and pharmacodynamics of milrinone lactate in pediatric patients with septic shock. J Pediatr 132:329-334, 1998.
16. Mikhail G, Gibbs J, Richardson M, Wright G, Khaghani A, Banner N, Yacoub M. An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension. Eur Heart J 18:1499-1504, 1997. (Pubitemid 27389046)
17. Moncada S. Eighth Gaddum Memorial Lecture. University of London Institute of Education, December 1980 Biological importance of prostacyclin. Br J Pharmacol 76:3-31, 1982.
18. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 55:601-607, 2005.
19. Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Internal Med 124:820-824, 1996.
20. Osinski MT, Rauch BH, Schror K. Antimitogenic actions of organic nitrates are potentiated by sildenafil and mediated via activation of protein kinase A. Mol Pharmacol 59:1044-1050, 2001.
21. Pappert D, Busch T, Gerlach H, Lewandowski K, Radermacher P, Rossaint R. Aerosolized prostacyclin versus inhaled nitric oxide in children with severe acute respiratory distress syndrome. Anesthesiology 82:1507-1511, 1995.
22. Radermacher P, Santak B, Wust HJ, Tarnow J, Falke KJ. Prostacyclin and right ventricular function in patients with pulmonary hypertension associated with ARDS. Intensive Care Med 16:227-232, 1990.
23. Ramamoorthy C, Anderson GD, Williams GD, Lynn AM. Pharmacokinetics and side effects of milrinone in infants and children after open heart surgery. Anesth Analg 86:283-289, 1998.
24. Rashid N, Morin FC, 3rd Swartz DD, Ryan RM, Wynn KA, Wang H, Lakshminrusimha S, Kumar VH. Effects of prostacyclin and milrinone on pulmonary hemodynamics in newborn lambs with persistent pulmonary hypertension induced by ductal ligation. Pediatr Res 60:624-629, 2006.
25. Roberts JD Jr, Fineman JR, Morin FC 3rd, Shaul PW, Rimar S, Schreiber MD, Polin RA, Zwass MS, Zayek MM, Gross I, Heymann MA, Zapol WM. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group. N Engl J Med 336:605-610, 1997.
26. Sablotzki A, Starzmann W, Scheubel R, Grond S, Czeslick EG. Selective pulmonary vasodilation with inhaled aerosolized milrinone in heart transplant candidates. Can J Anaesth 52:1076-1082, 2005.
27. Siostrzonek P, Koreny M, Delle-Karth G, Haumer M, Koller-Strametz J, Heinz G. Milrinone therapy in catecholamine-dependent critically ill patients with heart failure. Acta Anaesthesiol Scand 44:403-409, 2000.
28. Soditt V, Aring C, Groneck P. Improvement of oxygenation induced by aerosolized prostacyclin in a preterm infant with persistent pulmonary hypertension of the newborn. Intensive Care Med 23:1275-1278, 1997.
29. Steinhorn RH, Russell JA, Morin FC 3rd. Disruption of cGMP production in pulmonary arteries isolated from fetal lambs with pulmonary hypertension. Am J Physiol Heart Circ Physiol 268: H1483-H1489, 1995.
30. Van Heerden PV, Barden A, Michalopoulos N, Bulsara MK, Roberts BL. Dose-response to inhaled aerosolized prostacyclin for hypoxemia due to ARDS. Chest 117:819-827, 2000.
31. Walmrath D, Schneider T, Pilch J, Grimminger F, Seeger W. Aerosolised prostacyclin in adult respiratory distress syndrome. Lancet 342:961-962, 1993. (Pubitemid 23305501)
32. Walmrath D, Schneider T, Schermuly R, Olschewski H, Grimminger F, Seeger W. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med 153:991-996, 1996.
33. Walsh-Sukys MC, Tyson JE, Wright LL, Bauer CR, Korones SB, Stevenson DK, Verter J, Stoll BJ, Lemons JA, Papile LA, Shankaran S, Donovan EF, Oh W, Ehrenkranz RA, Fanaroff AA. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 105:14-20, 2000.
34. Xu HL, Wolde HM, Gavrilyuk V, Baughman VL, Pelligrino DA. cAMP modulates cGMP-mediated cerebral arteriolar relaxation in vivo. Am J Physiol Heart Circ Physiol 287: H2501-H2509, 2004.
35. Zobel G, Dacar D, Rodl S, Friehs I. Inhaled nitric oxide versus inhaled prostacyclin and intravenous versus inhaled prostacyclin in acute respiratory failure with pulmonary hypertension in piglets. Pediatr Res 38:198-204, 1995.
36. Zobel G, Gamillscheg A, Schwinger W, Berger J, Urlesberger B, Dacar D, Rigler B, Metzler H, Beitzke A. Inhaled nitric oxide in infants and children after open heart surgery. J Card Surg 39:79-86, 1998.
37. Zwissler B, Kemming G, Habler O, Kleen M, Merkel M, Haller M, Briegel J, Welte M, Peter K. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med 154:1671-1677, 1996.